08.02.2024 19:52:15
|
The Novozymes Report 2023
This annual report has been released subsequent to the approval of the combination of Novozymes and Chr. Hansen on January 29, 2024.
The new combined group is called Novonesis. As an annual report is required to cover the activities of a group during a financial year, this report only discloses Novozymes’ financial and non-financial performance in 2023. Non-financial elements concerning the combined group, Novonesis, are provided in separate and clearly labeled sections. Read more about Novonesis in the section The next step on our strategic journey.
This report does not include any realised, combined, proforma or stand-alone financials of Chr. Hansen or the combined entity Novonesis.
The Novozymes Annual Report 2023 is attached in XHTML and PDF.
Attachments


Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Novozymes A-S (B)mehr Nachrichten
11.02.25 |
Novonesis to acquire dsm-firmenich’s share of the Feed Enzyme Alliance (GlobeNewswire) | |
11.02.25 |
Erste Schätzungen: Novozymes A-S (B) öffnet die Bücher zum abgelaufenen Quartal (finanzen.net) | |
27.08.24 |
Ausblick: Novozymes A-S (B) mit Zahlen zum abgelaufenen Quartal (finanzen.net) |
Analysen zu Novozymes A-S (B)mehr Analysen
Aktien in diesem Artikel
Novozymes A-S (B) | 53,44 | -2,16% |
|